# Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

> **NCT06484868** · PHASE4 · RECRUITING · sponsor: **Amryt Pharma** · enrollment: 12 (estimated)

## Conditions studied

- Partial Lipodystrophy

## Interventions

- **DRUG:** Metreleptin

## Key facts

- **NCT ID:** NCT06484868
- **Lead sponsor:** Amryt Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-08
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484868, "Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06484868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*